You must login before you can post a comment..
We would be delighted if you would join us at Brewers Hall for the next Investor Briefing in our 2019 season, brought to you in partnership with Hardman & Co and in association with our sponsors City Index. Our focus this time around is life Sciences, and we would like to introduce you to some great investment opportunities.
Brewers Hall is an old-established City venue, just a short walk from Moorgate tube station and just off London Wall (EC2V 7HR)
Destiny Pharma plans to generate income and shareholder value by the clinical development and commercial exploitation of its proprietary, highly innovative anti-bacterial drug platform. The XF drug platform is being developed to prevent and treat existing and emerging superbug infections within and outside of hospitals.
The main market for the lead asset XF-73, which is currently in Phase 2 clinical studies, is the prevention of post-surgical infections such as MRSA. The commercial focus is initially in the USA but the need for a new treatment is global and Destiny Pharma has the ability to enter into licensing agreements and collaborations for other territories in due course. For example, the agreement signed in 2017 with China Medical Systems is a broad collaboration to develop the company’s assets in the China/Asia market.
The Board believes that the increasing governmental pressure and financial incentives that are being implemented now and possibly in the future by leading institutions such as the WHO, UN, FDA and G7/G20 will increase further the options available for profitable commercialisation and the generation of shareholder value.
Shield is a de-risked, commercial stage, specialty pharmaceutical company delivering innovative pharmaceuticals to address patients' unmet medical needs.
The Group has a marketed product, Feraccru®/Accrufer®, for the treatment of iron deficiency in adults which has exclusive IP rights until the mid-2030s.
Feraccru®/Accrufer® is approved by the FDA, EMA and Swiss Medic for the treatment of iron deficiency in adults and is commercialised in the European Union by Norgine BV, with a US commercialisation partner currently being selected.
Open Orphan plc is a European-focussed, rare and orphan drug consulting services platform. The Company consists of four elements: a European clinical research organisation and consultancy; an orphan drug services business; a Virtual Rep and Data Access Platform consisting of physicians and key opinion leaders; and a Health Data Platform to partner with Patient Advocacy Groups.
The Company is targeting rapid growth in one of the fastest growing sectors in the global pharmaceutical industry targeting under-supplied treatment for life threatening or very serious diseases and rare disorders.
For over 20 years, Hardman & Co has built a reputation for research of the highest quality, provided by a team of highly skilled and qualified industry professionals. The Life Sciences team, led by Dr Martin Hall, has a reputation for opinionated research that is distributed globally in the fields of pharmaceuticals, biotechnology, medical technology and healthcare.
Our strengths are industry knowledge, quality of product, and excellent distribution. Our reports tend to be more in-depth and more educational, but still getting messages across to all pools of capital, so they sit comfortably alongside, and are complementary to those of the company’s own broker.
Nigel Cassidy, our regular event presenter, is a highly experienced financial host, writer and broadcaster – perhaps best known for his years presenting the business news on BBC Radio 4’s iconic Today programme, and for the time he spent on the road as a roving TV business correspondent for BBC World News. He also hosted Share Radio’s breakfast show.
This event is suitable for sophisticated & private investors, private client brokers, fund managers, financial institutions, hedge funds, buy & sell side analysts and journalists. Be aware the price of stocks can go up and down and your capital is at risk.
Cathal Friel, CEO, Open Orphan (Ticker: ORPH / Index AIM & Euronext Growth / Sector: Services)
You must login before you can post a comment..
Meet 5 of the most innovative startups and learn more about their technologies....0.21 Miles Away
Come see our Fintech Insider podcast recorded live in London!...0.3 Miles Away
Join us for the first of our member events for a chance to network with others in the PropTech and wider property industry....0.58 Miles Away
Come see our Fintech Insider podcast recorded live in London!...
Mobilising finance for the Energy TransitionSpeaker ...
This is perfect for anyone looking to change careers, add to an existing skill set, or have a drink and explore some interesting topics....